Teladoc (TDOC) Reports Q3 Earnings: What Key Metrics Have to Say

Teladoc (TDOC) reported Q3 2025 revenue of $626.44 million, a 2.2% year-over-year decline, yet surpassed analyst estimates by 0.23%. The company posted an EPS loss of $0.21, outperforming the -$0.26 consensus. While the Integrated Care segment saw a 1.5% revenue increase and its Adjusted EBITDA exceeded expectations, the BetterHelp segment experienced a 7.8% revenue decrease year-over-year and significantly missed its Adjusted EBITDA forecast, highlighting divergent performance within its core business lines.

Analysis

Teladoc (TDOC) reported Q3 2025 revenue of $626.44 million, marking a 2.2% year-over-year decline, yet it marginally surpassed the Zacks Consensus Estimate of $625.02 million by 0.23%. The company posted an EPS loss of $0.21, which, while worse than the prior year's -$0.19, significantly beat the consensus estimate of -$0.26 by 19.23%, indicating better-than-expected bottom-line management.

Segment performance revealed a significant divergence. The Integrated Care segment showed strength with revenues growing 1.5% year-over-year to $389.54 million and Adjusted EBITDA reaching $66.07 million, both exceeding analyst estimates. U.S. Integrated Care Members also surpassed expectations at 102.5 million.

Conversely, the BetterHelp segment faced headwinds, experiencing a 7.8% year-over-year revenue decline to $236.9 million and its Adjusted EBITDA of $3.84 million fell substantially short of the $8.46 million estimate. BetterHelp Paying Users also slightly missed forecasts at 0.38 million, highlighting ongoing challenges in this key growth area.

Despite these mixed operational results, TDOC shares have outperformed the S&P 500 over the past month, returning +8.2% versus +3.8%. The stock currently holds a Zacks Rank #2 (Buy), suggesting potential near-term outperformance, which may reflect market optimism regarding the Integrated Care segment's resilience and the overall EPS beat.

Key Decisions for Investors

• Monitor the ongoing divergence in segment performance, particularly the ability of Integrated Care's growth to offset continued revenue and profitability challenges within the BetterHelp segment.
• Evaluate the sustainability of Teladoc's recent stock outperformance, considering the mixed fundamental signals including overall revenue contraction and the significant Adjusted EBITDA miss in BetterHelp.
• Assess whether the positive EPS surprise and Integrated Care's strong EBITDA beat are sufficient to drive long-term value, or if the BetterHelp segment's underperformance poses a material risk to future growth.